VRDN — Viridian Therapeutics, Inc.\DE

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1590750 ·
Last close
$30.06
Market Cap
$3.41B
52W High
$34.29
52W Low
$13.18
ADV30
2,650,719
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 25,752,000 24,225,000 -103,477,000 -101,209,000 1,028,670,000 172,860,000 447,972,000
Jun 2026 284,000 — -126,268,000 -127,119,000 1,097,233,000 164,986,000 435,136,000
Mar 2026 141,000 — -116,169,000 -104,901,000 789,017,000 176,346,000 153,009,000
Dec 2025 132,000 — -122,749,000 -120,355,000 899,418,000 212,382,000 177,251,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-341,505,000
Investing CF
$-468,979,000
Financing CF
$814,997,000
CapEx
$-11,939,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.84
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,671,687,000
Inventory
$85,000
Receivables
$29,782,000
ST Investments
$782,346,000
EBIT TTM
$-429,260,000
Pretax Income TTM
$-453,584,000
Interest Exp TTM
$24,324,000
Analysts
15

Yahoo Snapshot (yfinance, live)

Total Revenue
$26,309,000
EBITDA
$-467,961,984
Free Cash Flow
$-217,390,880
Enterprise Value
$2,623,595,264
Total Cash
$955,206,016
Total Debt
$245,496,992
Shares Out
113,558,449
Trailing EPS
$-3.85
Book Value
$4.25
ROE
-83.7%
ROA
-36.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 70,849,000 -363,395,000 -342,601,000 899,418,000 177,251,000 722,167,000 -276,391,000
Dec 2024 302,000 -299,035,000 -269,949,000 742,403,000 70,764,000 671,639,000 -232,319,000
Dec 2023 314,000 -254,450,000 -237,734,000 490,424,000 48,402,000 442,022,000 -184,170,000
Dec 2022 1,772,000 -134,304,000 -129,874,000 435,091,000 40,027,000 395,064,000 -93,838,000

TTM Snapshot

Revenues TTM
$71,127,000
NetIncome TTM
$-386,974,000
OpCashFlow TTM
—
Assets (Latest)
$1,097,233,000
Forward EPS
$-2.29

Max Pain — expiry 2027-01-15

max pain strike: $20.00 · spot: $30.12 · call oi: 1,028 · put oi: 366
Expected Move to 2027-01-15: ±$5.95 (19.75%) — implied range $24.17 – $36.07 · ATM straddle on $30.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
VKTX Viking Therapeutics, Inc. $3.43B $26.88 —
ELVN Enliven Therapeutics, Inc. $3.45B $46.85 —
ARQT Arcutis Biotherapeutics, Inc. $3.46B $27.33 —
IRON Disc Medicine, Inc. $3.49B $76.57 —
PBLS Parabilis Medicines, Inc. $3.49B $28.25 —

News headlines (Yahoo Finance, 1h cache)

Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says
2026-11-09 20:06 · Yahoo
Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
2026-11-09 12:01 · Yahoo
Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
2026-11-06 21:01 · Yahoo
Wall Street Analysts Predict a 39.68% Upside in Viridian Therapeutics (VRDN): Here's What You Should Know
2026-11-06 13:55 · Yahoo
Viridian Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-05 01:41 · Yahoo
Viridian Therapeutics (VRDN) Stock Looks Overvalued Even With Its New Launch
2026-11-05 01:09 · Yahoo
What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call
2026-11-04 22:14 · Yahoo
Viridian (VRDN) Q3 2026 Earnings Call Transcript
2026-11-04 19:45 · Yahoo
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 12:55 · Yahoo
Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
2026-11-04 12:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.